Author

Pavel Drastich 1

1 Institute for Clinical and Experimental Medicine,Department of Hepatogastroenterology,Prague,Czech Republic

CZECH REGISTRY OF INFLAMMATORY BOWEL DISEASE PATIENTS ON BIOLOGICAL THERAPY: RESULTS FROM THE FIRST YEAR

Martin Bortlík, Premysl Falt, Pavel Drastich, Tomas Douda, Michal Konecny, Vladimir Zboril, Milan Lukas

DE NOVO INFLAMMATORY BOWEL DISEASE AFTER ORTHOTOPIC LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS

Lukas Bajer, Pavel Drastich, Ludmila Prochazkova, Marek Benes, Julius Spicak

DISTINCT GUT MICROBIOTA PROFILES IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS AND ULCERATIVE COLITIS

Lukas Bajer, Miloslav Kverka, Martin Kostovcik, Peter Macinga, Jiri Dvorak, Zuzana Stehlikova, Jan Březina, Julius Spicak, Pavel Drastich

DUODENO-JEJUNAL BYPASS LINER FOR THE TREATMENT OF DIABETES MELLITUS IN OBESE PATIENTS: COMPLETENESS OF DUODENAL BLINDING AS THE KEY FACTOR FOR EFFICACY

Marek Benes, Pavel Drastich, Tomas Hucl, Julius Spicak

FAECAL MICROBIAL TRANSPLANTATION VERSUS 5-ASA ENEMA FOR TREATMENT OF ACTIVE LEFT-SIDED ULCERATIVE COLITIS – RESULTS FROM RANDOMIZED CONTROL TRIAL FACTU

Jan Březina, Ales Novotny, Dana Duricova, Jana Kozeluhova, Pavel Hrabak, Katerina Fliegerová, Jakub Mrazek, Simona Kvasnová, Chahrazed Mekadim, Lukas Bajer, Julius Spicak, Milan Lukas, Pavel Drastich, Pavel Wohl

FINAL RESULTS OF MULTI-CENTER, PROSPECTIVE, CONTROLLED TRIAL OF THE DUODENO-JEJUNAL BYPASS LINER FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN OBESE PATIENTS: EFFICACY AND FACTORS PREDICTING A SUBOPTIMAL EFFECT

Marek Benes, Pavel Drastich, Tomas Hucl, Julius Spicak

Gut microbiota in primary sclerosing cholangitis is characterized by specific composition of fungi

Lukas Bajer, Natalie Galanova, Peter Macinga, Jan Březina, Martin Kostovcik, Klara Kostovcikova, Julius Spicak, Miloslav Kverka, Pavel Drastich

IBD PHENOTYPES DIFFER IN GUT MYCOBIOTA COMPOSITION

Pavel Drastich, Lukas Bajer, Klara Klimesova, Martin Kostovcik, Miloslav Kverka, Jan Březina, Julius Spicak

INTERIM RESULTS OF A MULTI-CENTER, PROSPECTIVE, CONTROLLED TRIAL OF THE DUODENAL-JEJUNAL BYPASS LINER FOR THE TREATMENT OF TYPE 2 DIABETES IN OBESE PATIENTS: ARE THERE ANY FACTORS PREDICTING A SUB-OPTIMAL EFFECT?

Marek Benes, Tomas Hucl, Pavel Drastich, Julius Spicak

INTESTINAL DYSBIOSIS IN PATIENTS WITH SHORT BOWEL SYNDROME DEPENDENT ON TOTAL PARENTERAL NUTRITION IS REFLECTED BY ALTERED METABOLOME IN FAECES

Lukas Bajer, Martin Kostovcik, Jaromir Hradecky, Tomas David, Petr Wohl, Julius Spicak, Pavel Drastich, Monika Cahova

Item 1 - 10 / 29
1
2 3